Navigation Links
Agendia Presents Data Supporting MammaPrint's Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
Date:3/11/2009

HUNTINGTON BEACH, California, and AMSTERDAM, The Netherlands, March 11 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia and the Netherlands Cancer Institute will present data from multiple studies at the 2009 St.Gallen Breast Cancer Conference. The St. Gallen Breast Cancer Conference, one of the premiere conferences in breast cancer research worldwide, takes place March 11th-14th, 2009 in St.Gallen, Switzerland.

The study results further underpin the predictive and prognostic power of Agendia's breast cancer recurrence test, MammaPrint(R) and will be discussed at the following poster sessions:

Thursday, 12 March 2009

Poster 0063

Comparison of MammaPrint and TargetPrint Results with Clinical Parameters in German Patients (PATH) with Early Stage Breast Cancer

G. Kunz, T. Dimpfl, C. Jakisch, R. Buttner, F. A. de Snoo, O. Krijgsman, E. van Lienen, A. Glas, and R. Bender.

Thursday, 12 March 2009

Poster 0071

The 70 Gene-MammaPrint Profile Allows to Identify a Subgroup of Good-Prognostic Patients with Primary Breast Cancer and 4-9 Positive Lymph Nodes

M. Saghatchian, S. Mook, G. Pruneri, G. Viale, A. Glas, I. Eekhout, M. Knauer, and LJ van 't Veer.

Thursday, 12 March 2009

Poster 0072

The 70-gene MammaPrint Prognosis Signature for Optimal Risk Stratification in Endocrine Responsive Breast Cancer

M Knauer, EJT Rutgers, S Mook, F Cardoso, MJ van de Vijver, G Viale, AM Glas, M. Saghatchian, M Kok, JM Bueno-de-Mesquita, SC Linn and LJ van 't Veer.

Thursday, 12 March 2009

Poster 0073

The 70-gene MammaPrint Signature Is Predictive for Chemotherapy Benefit in Early Breast Cancer

M Knauer, ME Sraver, EJT Rutgers, RA Bender, F Cardoso, S Mook, MJ van de Vijver, M. Saghatchian, RHT Koornstra, JM Bueno-de-Mesquita, S Rodenhuis, SC Linn and LJ van 't Veer.

Thursday, 12 March 2009

Poster 0074

Early Prognosis Prediction: MammaPrint on Core-needle biopsies

F. de Snoo, A. Glas, A. Floore, J. Mayordomo, A. Modollel, C. Rolfo, LJ van 't Veer, E. Rutgers, S. Rodenhuis, and R. Bender.

Thursday, 12 March 2009

Poster 0075

Use of the Genomic Test MammaPrint in Daily Clinical Practice to Assist in Risk Stratification of Young Breast Cancer Patients

G. Kunz, A. Glas and F. de Snoo, I. Simon.

About MammaPrint(R)

MammaPrint is the first 'in vitro diagnostic multivariate index assay' (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-those patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test result provides a doctor with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer treatments. The company markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
2. Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
3. Agendia Appoints VP of Business Development
4. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
5. Agendia Appoints New Chief Financial Officer
6. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
7. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
8. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
9. Agendia BV Appoints Clinical and Scientific Advisory Board
10. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
11. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
(Date:6/22/2016)... June 22, 2016 Research and Markets has ... report to their offering. ... 2014 from $29.3 billion in 2013. The market is expected to ... from 2015 to 2020, increasing from $50.6 billion in 2015 to ... forecasts during the forecast period (2015 to 2020) are discussed. As ...
Breaking Biology Technology:
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
Breaking Biology News(10 mins):